IBD DIAGNOSIS IS CHALLENGING
The Global Impact of Inflammatory Bowel Diseases (IBD)
Inflammatory Bowel Diseases (IBD) pose a substantial health burden worldwide, affecting approximately 0.5% of the global population, with an estimated 10 million individuals grappling with this condition.
Challenges of Current Diagnostic Methods
Existing non-invasive blood and fecal tests lack the necessary specificity for diagnosing IBD, often failing to accurately identify inflammation severity and locations. Moreover, they provide no molecular information that could guide treatment.
Diagnostic Pitfalls in Ileal Crohn's Disease (CD)
In cases of ileal Crohn's disease (CD), conventional fecal calprotectin testing frequently produces unreliable results, contributing to diagnostic challenges with significant rates of false positives and false negatives.
The Imperative of Endoscopic Remission
Achieving endoscopic remission, a pivotal treatment objective in managing IBD, typically relies on invasive procedures such as endoscopies, associated with the acquisition of biopsies.
INTRODUCING OUR
REVOLUTIONARY SOLUTION
Offering a reliable, non-invasive solution that accurately identifies inflammation locations, thereby improving patient care and treatment outcomes.
Tracells' stool test utilizes RNA profiles from patients' epithelial and immune cells, which are shed into the stool, for accurate IBD diagnosis.
AI-driven analysis offers insights into inflammation severity and location.
Transcriptomics of shed cells in fecal washes provides molecular signatures of inflammation in IBD
Fecal washes can detect inflammation with high precision (95% sensitivity and 79% specificity).
Tracells holds the knowledge to recap these results from stool samples to precisely identify the severity and location of inflammation.
